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Abstract
Background & Aims—Hepatopulmonary syndrome (HPS) affects 10%–30% of patients with
cirrhosis and portal hypertension and significantly increases mortality. Studies in experimental
models indicate that pulmonary angiogenesis contributes to the development of HPS, but
pathogenesis in humans is poorly understood. We investigated genetic risk factors for HPS in patients
with advanced liver disease.
Methods—We performed a multicenter case-control study of patients with cirrhosis being evaluated
for liver transplantation. Cases had an alveolar-arterial oxygen gradient ≥15 mm Hg (or ≥20 mm Hg
if age > 64 years) and contrast echocardiography with late appearance of microbubbles after venous
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injection of agitated saline (intrapulmonary vasodilatation); controls did not meet both criteria for
case status. The study sample included 59 cases and 126 controls. We genotyped 1086 common
single nucleotide polymorphisms (SNPs) in 94 candidate genes.
Results—Forty-two SNPs in 21 genes were significantly associated with HPS after adjustments
for race and smoking. Eight genes had at least 2 SNPs associated with disease: CAV3, ENG, NOX4,
ESR2, VWF, RUNX1, COL18A1, and TIE1. For example, rs237872 in CAV3 showed an odds ratio
of 2.75 (95% confidence interval: 1.65–4.60, P =.0001) and rs4837192 in ENG showed an odds ratio
of 0.35 (95% confidence interval: 0.14–0.89, P =.027). Furthermore, variation in CAV3 and
RUNX1 was associated with HPS in gene-based analyses.
Conclusions—Polymorphisms in genes involved in the regulation of angiogenesis are associated
with the risk of HPS. Further investigation of these biologic pathways might elucidate the
mechanisms that mediate the development of HPS in certain patients with severe liver disease.
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The hepatopulmonary syndrome (HPS) occurs when vascular alterations in the pulmonary
microvasculature lead to abnormalities in systemic oxygenation in the setting of liver disease
or portal hypertension.11 This syndrome is found in 10%–30% of patients with cirrhosis being
evaluated for liver transplantation, and we and others have shown that HPS is associated with
worse quality of life and increased mortality.2–4 Currently, the only established treatment for
HPS is liver transplantation, although postoperative survival may be lower in patients with
HPS relative to those without HPS.5 Together, these observations support the need to define
the pathogenesis of HPS to develop effective medical therapies. Identification of genetic risk
factors for this prevalent and morbid complication of liver disease could suggest novel
therapeutic approaches.
The mechanisms for HPS in patients with cirrhosis are unclear. Early experimental and human
studies implicated pulmonary microvascular dilation, in part related to excess nitric oxide
production and altered estrogen signaling in disease pathogenesis.6–8 Although impaired
vasomotor tone contributes to the pathophysiology of HPS, incomplete response to
pharmacologic blockade of these pathways implies additional mechanisms.9,10 Observations
of increased angiogenesis in the splanchnic and hepatic microvascular beds11 and increased
pulmonary capillary density12 in advanced liver disease suggest that vascular remodeling and
pulmonary angiogenesis may also play a role. This hypothesis is supported by the recent
demonstration of increased in pulmonary microvessels as well as up-regulation of vascular
endothelial growth factor-mediated angiogenic pathways in the common bile duct-ligated rat,
an animal model of human HPS.13
We therefore hypothesized that variation in genes responsible for vascular phenotype and
homeostasis contributes to the risk of developing HPS. We performed a high-throughput
candidate gene study in an attempt to identify common genetic variation associated with the
risk of HPS in a group of patients undergoing liver transplantation evaluation. This work has
been previously published in abstract form.14
Patients and Methods
For other information regarding patients and methods, please see Supplementary Patients and
Methods.
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Study Cohort and Study Sample
The Pulmonary Vascular Complications of Liver Disease Study enrolled a cohort of 536
patients evaluated for liver transplantation at 7 centers in the United States between 2003 and
2006. The only inclusion criterion was the presence of chronic portal hypertension with or
without intrinsic liver disease. We excluded patients with evidence of active infection, recent
(<2 weeks) gastrointestinal bleeding, or those who had undergone liver or lung transplantation.
The institutional review boards at each of the participating centers approved this study, and
informed consent was obtained.
We performed a case-control study. The study sample included new patients from the
Pulmonary Vascular Complications of Liver Disease Study cohort evaluated with contrast
transthoracic echocardiography, spirometry, and arterial blood gas sampling (routinely
performed for pretransplant evaluation) during the study period with available genetic data.
We excluded patients with pulmonary function testing showing a significant obstructive or
restrictive ventilatory defect (see Supplementary Patients and Methods). We also excluded
patients with intracardiac shunting (or with uninterpretable shunt timing) by transthoracic
echocardiography as described below.
Contrast transthoracic echocardiography was performed and interpreted at each center.
Agitated saline was injected via a peripheral vein during imaging. Appearance of microbubbles
in the left heart ≥ 3 cardiac cycles after venous injection of agitated saline was considered
“late,” consistent with intrapulmonary shunting. Appearance of microbubbles in the left heart
< 3 cardiac cycles after venous injection was considered “early,” consistent with intracardiac
shunting.
Case and Control Definitions
Cases and controls were identified from those patients fulfilling the inclusion and exclusion
criteria defined above. HPS was defined by (1) contrast echocardiography with late appearance
of microbubbles after venous injection of agitated saline and (2) an alveolar-arterial (A-a)
oxygen gradient ≥15 mm Hg (or ≥20 mm Hg if age > 64 years), as recommended by the
European Respiratory Society Task Force Pulmonary-Hepatic Vascular Disorders Scientific
Committee.1 Patients who did not meet both criteria were considered in the “non-HPS” group
(controls). Patients with either “early” or indeterminate timing of the appearance of
microbubbles in the left heart after agitated saline injection were excluded from the study.
Clinical Variables and Blood Sampling
Data were collected from subjects and the medical record. The Model for End-stage Liver
Disease score was calculated, without inclusion of exception points for either hepatocellular
carcinoma or HPS.15 Phlebotomy was performed, and blood was collected into EDTA-
containing tubes. Plasma and buffy coat layers were stored at −80°C.
Candidate Genes and Single Nucleotide Polymorphism Selection
Ninety-four genes affecting vascular function were selected by the investigators (Table 1). For
this study, 1086 single nucleotide polymorphisms (SNP) in the 94 candidate genes were
genotyped (Supplementary Table 1). We genotyped an additional set of 61 SNPs (null loci)
from a validated list of Ancestry Informative Markers (AIM)16 to detect potential population
stratification. (See Supplementary Patients and Methods for details of gene and SNP selection.)
Genotyping
Genomic DNA was isolated from peripheral leukocytes using standard procedures (Gentra
Puregene; Qiagen, Valencia, CA). SNP genotyping was performed using the GoldenGate
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Assay (Illumina, Inc, San Diego, CA). SNP assays that failed to generate results in >10% of
subjects were considered to have failed and not used for analyses.
Statistical Analysis
Continuous data were summarized using mean ± standard deviation or median (interquartile
range), as appropriate. Categorical variables were summarized using number and percentage.
To test for differences in covariates between cases and controls, Student t tests, Wilcoxon rank-
sum tests, χ2 tests, and Fisher exact tests were used, as appropriate.
Genotype distributions were tested for consistency with expected Hardy–Weinberg
equilibrium (HWE) proportions in controls. Single locus association analyses were assessed
assuming an additive genetic model using multivariable logistic regression, with adjustment
for race and smoking (previously associated with case status4). The association of genotype
with case/control status was expressed with odds ratios (ORs). Potential population
stratification within our sample was tested using multidimensional scaling using AIM.17 These
analyses were performed in PLINK v1.02 (http://pngu.mgh.harvard.edu/purcell/plink/).18
For genes in which more than 1 SNP was associated with HPS, we identified linkage
disequilibrium blocks containing 3 or more SNPs using Haploview 4.0.19 We used an
expectation-maximization algorithm to estimate haplotypes. Association between disease
status and haplotypes was assessed using a generalized linear model approach via the R package
Haplo.stats.20 Both global tests of haplotype association and haplotype-specific analysis
(providing ORs with respect to a referent haplotype) were conducted.
Principal component (PC) regression analysis was used to synthesize information across
several SNPs within a gene in a gene-based approach.21,22 Each SNP was assigned a score
based on the per-allele model, and PCs were constructed to be linear combinations of these
scores. We used the PCs in a logistic regression model to investigate the association between
each gene and case status. For each gene, we calculated PCs using the pcreg procedure in R.
23
In a second gene-based approach, we used classification and regression trees (CART) to help
select a small initial subset of interesting markers with high probability for further investigation.
24 In the CART analysis, we specified a minimum group size of 7 and minimum splitting size
of 20 in R. Furthermore, we conducted a Random Forests analysis, which creates an ensemble
of CART trees using random two-thirds samples of the data then tests the tree with the
remaining one third of the data.25 Missing data were replaced using the multiple imputation
algorithm and the Random Forests algorithm.
There was 80% power to detect ORs of ≥ 1.91–3.92 (or ≤0.26–0.52), depending on the minor
allele frequency of the SNP (0.05–0.45). Power analysis was performed using QUANTO
1.2.26 Because the main goal of this study was hypothesis generation, adjustment for multiple
comparisons was not performed. P <.05 was considered significant for all analyses.
Results
There were 59 cases and 126 controls included in this analysis (Table 2). The mean age of the
subjects was 53 ± 10 years, 39% were female, and the majority (83%) was non-Hispanic. The
majority of subjects in both groups had liver disease because of hepatitis C infection (44%) or
alcohol (41%). Subjects with HPS had a mean PaO2 of 75 ± 13 mm Hg and a median alveolar-
arterial oxygen gradient of 25 mm Hg (interquartile range, 19–35 mm Hg).
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Of the 1086 SNPs genotyped in candidate genes, 3 assays failed, 13 SNPs were monomorphic,
and 65 SNPs did not conform to HWE (P <.05), leaving 1005 SNPs in the analysis. Of the 61
AIM SNPs, 3 were out of HWE (P <.05) and were thus not used for assessment of population
stratification. There was no evidence of population stratification in our study population based
on these AIMs.
Single SNP Analysis
Forty-two SNPs in 21 genes were significantly associated with HPS after adjustment for race
and smoking (Table 3). Thirty-two of these SNPs were clustered in 8 genes: Caveolin 3
(CAV3); Endoglin (ENG); NADPH Oxidase 4 (NOX4); Estrogen receptor 2 (ESR2); von
Willebrand Factor (VWF); Runt-related transcription factor 1 (RUNX1); Collagen, type XVIII,
α-1 (COL18A1); and Tyrosine kinase with immunoglobulin g and EGF Factor homology
domains (TIE1). Polymorphisms associated with an increased risk of HPS included 2 CAV3
SNPs, rs237872 (OR, 2.75; 1.65–4.60, P =.0001) and rs237875 (OR, 2.11; 1.29–3.45, P =.
003). In addition, a missense variant (R126C) in spermidine/spermine N1-acetyltrans-ferase
family member 2 (SAT2), a regulator of Hypoxia-inducible factor 1, α subunit (HIF1A) activity,
was associated with HPS (OR, 3.65; 1.43–9.31, P =.007).
Other variants that were associated with the risk of HPS included 2 tightly linked (D′ = 0.969,
r2 = 0.912) intron 1 SNPs in ENG, rs4836585 (OR, 0.38; 0.15-1.00, P =.49) and rs4837192
(OR 0.35, 0.14–0.89, P =.027). In addition, 2 NOX4 SNPs (rs585197 and rs2164521) were
associated with case status in our subjects. Among genes in steroid hormone signaling
pathways, 4 of 14 tested SNPs in ESR2 affected the risk for HPS, as did a steroid hormone
binding globulin (SHBG) missense variant in exon 4 (P184L).
Finally, 10 of 11 associated SNPs in VWF conferred an increased risk for HPS (OR, 1.66–
2.18). One of these SNPs, rs1063856, encodes a missense variant (T789A) in exon 18
previously demonstrated to associate with higher circulating levels of VWF.27 In our cohort,
possession of the alanine allele was significantly associated with case status (OR, 2.18; 95%
confidence interval [CI]: 1.35–3.52, P =.002).
Haplotype Analyses
The haplotype block 3 of CAV3, (Table 4, Supplementary Figure 1) was significantly associated
with the risk for HPS (Global, P =.003). Haplotype-specific analyses demonstrated that
possession of haplotype AGAAA confers the greatest increase in HPS risk (OR, 5.28; 95% CI:
2.02-13.82, P =.0009) in comparison with the most common haplotype. In VWF, haplotype
block 6 (Table 4, Supplementary Figure 2) was significantly associated with HPS (Global, P
=.008). In the individual haplotype analysis, the possession of the rare haplotype CGAGG was
associated with a significantly lower risk of HPS (OR, 0.21; 95% CI: 0.06–0.76, P =.02).
Gene-Based Analyses
Elastase 1 (ELA1) (P <.005), CAV3 (P <.04), BMPR2 (P <.03), and NFKB1 (P <.03) were all
significantly associated with HPS in the PC analysis. In the CART analysis, the following
SNPs were identified as being most predictive of HPS phenotype: rs2834650 (RUNX1),
rs1800472 (TGFB1), rs11224779 (TRPC6), rs429342 (PRKCB1), and rs237870 (CAV3)
(Figure 1). The Random Forests algorithm was run 1000 times, and the 3 most important SNPs
identified in each iteration were recorded. The following SNPs were most frequently identified
as being influential: rs2834650 (RUNX1), rs2274751 (TNC), rs3729904 (PRKCB1), rs1800472
(TGFB1), rs237872 (CAV3).
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Using a hypothesis-generating approach, we have identified that the possession of common
genetic variation in genes associated with vascular growth and development and estrogen
action and signaling was associated with HPS in this case-control study. In contrast, we did
not find any association between HPS and vasoregulatory genes such as nitric oxide, heme
oxygenase, and the endothelin-B receptor, which have been specifically implicated in HPS.
28–31 Our findings are in line with recent experimental results that demonstrate an important
role for pulmonary angiogenesis in HPS.13
We have identified a number of genetic risk factors for HPS that modulate angiogenesis or
vascular development. For example, endostatin, the proteolytic fragment of the C-terminus
COL18A1, inhibits angiogenesis.32,33 In addition to the genetic association reported here, we
have recently demonstrated that overexpression of endostatin in an animal model of HPS blocks
the expansion of pulmonary microvessels as well as the oxygen diffusion impairment
characteristic of that model.13 Endoglin is a transmembrane auxillary receptor for transforming
growth factor (TGF)-β that is predominantly expressed on proliferating endothelial cells.
Mutations in endoglin and activin receptor-like kinase 1 (ALK1), an endothelial specific TGF-
β type I receptor, have been linked to hereditary hemorrhagic telangiectasia, an autosomal
dominant vascular dysplasia characterized by telangiectasias and arteriovenous malformations.
34,35 Interestingly, among patients with hereditary hemorrhagic telangiectasia, pulmonary
arteriovenous malformations are significantly more likely in subjects with endoglin mutations.
36 Last, TIE1, an endothelial specific receptor tyrosine kinase, is essential for the activation of
TIE2 by vascular endothelial growth factor (VEGF), thus modulating vascular remodeling and
blood vessel development.37
Low oxygen tension (hypoxia) is a potent stimulator of vascular growth and remodeling, and,
in the pulmonary vasculature, oxygen sensing is critical for maintenance of normal gas
exchange via adjustments in vascular tone. Four of the genes implicated here–HIFA1, SAT2,
RUNX1 and NOX4–play central roles in oxygen-dependant vascular phenotypes. HIF1A
stimulates endothelial cell angiogenesis under hypoxic conditions by activating the
transcription of numerous transcription and growth factors38 and is regulated by SAT2.39
Variation in both genes was associated with HPS case status. RUNX1 is a hematopoetic
transcription factor that contributes to the angio- and vasculogenic phenotype via its interaction
with other transcription factors such as HIF1A and insulin growth factor binding protein
3.40–42 Last, NOX4 is one of the enzymes responsible for generation of reactive oxygen species
in endothelial cells that modulate angiogenesis and has been implicated in hypoxia-induced
proliferation.43 These results identify variation in specific genes that may contribute to
susceptibility in HPS and be candidates for future studies.
Three specific signaling pathways–carbon monoxide, nitric oxide, and endothelin–have been
implicated in pulmonary vasodilatation in experimental and human HPS. Increased production
of the gaseous vasodilators nitric oxide and carbon monoxide has also been associated with
vascular dilatation in HPS,30,44,45 and, thus, we tested variants in the inducible and endothelial
forms of nitric oxide synthase (NOS) as well as heme oxygenase 1 (HMOX1), the rate-limiting
enzyme in the production of carbon monoxide. A recent report found that the Glu298Asp
(rs1799983) variant in NOS3 was associated with risk of HPS in 20 subjects with pediatric
(predominately anatomic or metabolic) liver disease. We did not replicate this observation in
our cohort (OR, 0.75; 95% CI: 0.43–1.31, P =.31). Altered endothelin signaling has been
implicated in experimental HPS, with the liver producing increased circulating ET-1, which
signals through up-regulated ET-B receptors on pulmonary endothelial cells.46 We analyzed
SNPs in endothelin converting enzyme as well as both endothelin A and B receptors. Germ-
line variation in none of these genes was associated with risk of HPS in our study population.
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In addition to our single SNP analyses, we undertook gene- and pathway-based approaches to
provide additional insight into the relationship between genotype and disease phenotype. Two
genes with single SNP associations–CAV3 and RUNX1–were also identified in these analyses.
CAV3 gene had an overall association with HPS using PC analysis, and SNPs from CAV3 were
found in the CART and Random Forests approaches. A SNP from RUNX1 was identified as
the most discriminating polymorphism (first split) in the CART tree, and this was confirmed
by the Random Forests algorithm. Because these 2 genes were shown to be important using
multiple methodologies, this provides stronger evidence that CAV3 and RUNX1 are associated
with HPS. In addition to supporting these associations, these analyses also indicated 3 genes
not found in the single SNP analysis—TGFB1, TNC, and TRPC6–may actually be associated
with the disease.
There are several limitations to this study. First, the sample size was small, limiting our ability
to find genetic alleles associated with HPS that were rare, had small effect sizes, or whose
effect depended on gene-gene or gene-environment interaction. However, this is the largest
reported epidemiologic study of HPS with strict case and control phenotypes and the first in
HPS to employ high-throughput genotyping.
A fundamental challenge in high-throughput genetic analyses is the control of type I error.
Given that we analyzed multiple SNPs for each of more than 90 genes, we can reasonably
expect a certain number of statistically significant associations because of chance alone. We
attempted to minimize the chance of “false-positives” by using a curated candidate gene list,
thusly increasing the prior probability that one or more of these genes has mechanistic
importance in HPS. There are commonly utilized frequentist methods to adjust for multiple
comparisons in high-throughput studies, such as the Bonferroni correction and false discovery
rate.47 Both methodologies assume that the association of each individual SNP with case status
is entirely independent of those of the other SNPs. We have documented patterns of linkage
disequilibrium between genotyped SNPs (data not shown). Because most accepted methods
to account for multiple comparisons do not consider such relatedness, they are overly
conservative for this purpose. We have therefore presented the results without adjustment and
consider these results to be hypothesis generating. Whereas replication would be important,
the biologic plausibility of our findings, the multiple gene “hits” in certain pathways, and the
demonstration of association via both single loci and gene-based approaches is reassuring that
type I error does not explain the findings.
In conclusion, our results implicate common genetic variation in the pathogenesis of HPS.
Future studies should focus on replication in other populations and the mechanisms that explain
the associations between the SNPs of interest and HPS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used in this paper
95% Cl 95% confidence interval
AIM Ancestry Informative Marker
CART classification and regression trees
CAV3 Caveolin 3
COL18A1 collagen, type XVIII, α-1
ENG endoglin
ESR2 Estrogen receptor 2
HIF1A Hypoxia-inducible factor 1, α subunit
HPS hepatopulmonary syndrome
HWE Hardy-Weinberg equilibrium
MELD Model for End-stage Liver Disease
NOX4 NADPH Oxidase 4
OR odds ratio
PC principal component regression analysis
RUNX1 Runt-related transcription factor 1
SAT2 Spermidine/spermine N1-acetyltransferase family member
SHBG Steroid hormone binding globulin
SNP single nucleotide polymorphism
TIE1 Tyrosine kinase with Ig and EGF factor homology domains 1
VWF von Willebrand factor
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Classification and regression tree (CART). Each split in the tree maximizes the separation of
cases and controls based on SNP genotypes.
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Table 1
Candidate Genes: Gene Ontology Annotation
Pathway Gene Reference sequence Chr SNPs
Control of blood circulation GO:
0008015
Angiotensin I converting enzyme (ACE) NM_152831 17q23 15
Elastin (ELN) NM_000501 7q11 5
Endothelin 1 (EDN1) NM_001955 6p24 7
Endothelin converting enzyme 1 (ECE1) NM_001397 1p36 10
Endothelin receptor, nonselective type (EDNRB) NM_000115 13q22 13
Endothelin receptor, type A (EDNRA) NM_001957 4q31 11
Heme oxygenase 1 (HMOX1) NM_002133 22q13 8
Natriuretic peptide precursor A (NPPA) NM_006172 1p36 13a
Natriuretic peptide precursor B (NPPB) NM_002521 1p36 13a
Nitric oxide synthase 2 (NOS2A) NM_000625 17q11 15
Phosphodiesterase 5 (PDE5A) NM_001083 4q26 9
Potassium channel, voltage-gated, shaker, member 5
(KCNA5)
NM_002234 12p13 9
Rho-associated protein kinase 2 (ROCK2) NM_004850 2p24 15
Transient receptor potential cation channel, subfamily C, 6
(TRPC6)
NM_004621 11q21 18
Cell growth Activin A receptor, type II-like kinase (ACVRL1) NM_000020 12q11 6
Apoptosis GO:0008283
GO:0006915
Apolipoprotein E (APOE) NM_000041 19q13 4
BCL2-associated X protein (BAX) NM_138764 19q13 6
Bone morphogenetic protein receptor type 1a (BMPR1A) NM_004329 10q22 20
Bone morphogenetic protein receptor type 2 (BMPR2) NM_001204 2q33 12
Caveolin 1 (CAV1) NM_001753 7q31 20a
Caveolin 2 (CAV2) NM_001233 7q31 20a
Caveolin 3 (CAV3) NM_033337 3p25 19
CD14 molecule (CD14) NM_000591 5q22 3
Cyclin-dependent kinase inhibitor 2A (CDKN2A) NM_000077 9p21 13
Growth differentiation factor 2 (GDF2) NM_016204 10q11 5
Homolog of drosphila mothers against dpp 3 (SMAD3) NM_005902 15q21 34
Homolog of drosphila mothers against dpp 4 (SMAD4) NM_005359 18q21 5
Nitric oxide synthase 3 (NOS3) NM_000603 7q36 10
Nuclear factor κB p100 subunit (NFKB2) NM_001077493 10q24 5
Nuclear factor κB p105 subunit (NFKB1) NM_003998 4q23 13
Nuclear factor κB p65 subunit (RELA) NM_021975 11q13 4
Prostaglandin I2 synthase (PTGIS) NM_000961 20q13 13
Protein kinase C, α (PRKCA) NM_002737 17q22 33
Protein kinase C, β 1(PRKCB1) NM_002738 16p11 13
Protein kinase C, γ (PRKCG) NM_002739 19q13 5
Transforming growth factor, β-1 (TGFβ1) NM_000660 19q13 5
V-AKT murine Thymoma viral oncogene homolog 1
(AKT1)
NM_005163 14q32 7
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Pathway Gene Reference sequence Chr SNPs
Blood vessel growth and development
GO: 0001568
Angiopoietin 1 (ANGPT1) NM_001146 8q22 37
Calcium-binding protein A4 (S100A4) NM_019554 1q21 6
Endoglin (ENG) NM_000118 9q34 15
Hypoxia-inducible factor 1, α subunit (HIF1A) NM_001530 14q21 8
Plasminogen (PLG) NM_000301 6q26 21
Runt-related transcription factor 1 (RUNX1) NM_001754 21q22 58
Thrombospondin-1 (THBS1) NM_003246 15q15 5
Tyrosine kinase with Ig and EGF Factor homology domains
(TIE1)
NM_005424 1p34 8
Vascular endothelial growth factor (VEGF) NM_00125366 6p12 7
Inflammation GO:0006954 Complement component 4A (C4A) NM_007293 6p21 4
C-reactive protein (CRP) NM_000567 1q21 8
Cytochrome b-245, NADPH Oxidase 2, NOX2 (CYBB) NM_000397 Xp21 6
Lipopolysaccharide binding protein (LBP) NM_004139 20q11 7
Tumor necrosis factor (TNF) NM_000594 6p21 5
Oxidation reduction GO: 0006979 Dual oxidase 1 (DUOX1) NM_017434 15q15 15a
Dual oxidase 2 (DUOX2) NM_014080 15q15 15a
NADPH Oxidase 1 (NOX1) NM_007052 Xq22 7
NADPH Oxidase 4 (NOX4) NM_016931 11q14 19
Superoxide dismutase 1, soluble (SOD1) NM_000454 21q22 3
Superoxide dismutase 2, mitochondrial (SOD2) NM_00636 6q25 3
Xanthine dehydrogenase (XDH) NM_00379 2p23 24
Tissue development GO:0009888 Homolog of drosphila mothers against dpp 2 (SMAD2) NM_005901 18q21 10
Ikaros (IKZF1) NM_006060 7p12 7
Peroxisome proliferator activated receptor, γ (PPARG) NM_005037 3p25 13
Recombination signal-binding protein 1 for J-κ (RBPSUH) NM_005349 4p15 13
Steroid hormone GO:0008202
GO:0030518
Aromatase (CYP19A1) NM_000103 15q21 24
Estrogen receptor 1 (ESR1) NM_000125 6q25 36
Estrogen receptor 2 (ESR2) NM_001437 14q24 14
Farnesoid × receptor (NR1H4) NM_005123 12q 7
Pregnane × receptor (NR1I2) NM_003889 3q13 13
Sex hormone binding globulin (SHBG) NM_001040 17p13 6
Small heterodimer partner (NR0B2) NM_021969 1p36 5
Extracellular matrix structure and
regulation GO:0043062
GO:0006508
Collagen, type XVIII, α-1 (COL18A1) NM_130445 21q22 29
Elastase 1 (ELA1) NM_001971 12q13 8
Elastase 2 (ELA2) NM_001972 19p13 4
Matrix metalloproteinase 2 (MMP2) NM_004530 16q13 11
Matrix metalloproteinase 3 (MMP3) NM_002422 11q23 6
Matrix metalloproteinase 9 (MMP9) NM_004994 20q11 6
Proteinase inhibitor 3; elafin (PI3) NM_002638 20q12 4
Tenascin C (TNC) NM_002160 9q33 16
Coagulation GO:0050817 Plasminogen activator inhibitor 1 (SERPINE1) NM_000602 7q21 9
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Pathway Gene Reference sequence Chr SNPs
Thrombomodulin (THBD) NM_000361 20p11 4
Thromboplastin (HEMB) NM_000133 Xq27 11
Von Willebrand factor (VWF) NM_000552 12p13 39
Serotonin GO:0006587
GO:0007210
Serotonin 2B receptor (HTR2B) NM_000867 2q36 8
Serotonin transporter (SLC6A4) NM_001045 17q11 7
Tryptophan hydroxylase (TPH1) NM_004179 11p15 8
Tryptophan hydroxylase 2 (TPH2) NM_173353 12q21 16
Na/bile acid transporter GO:0008508 Solute carrier family 10, member 1 (SLC10A1) NM_003049.1 14q24 5
Solute carrier family 10, member 2 (SLC10A2) NM_000452.1 13q33 12
Metabolism GO:0008152 5,10-Methylenetetrahydrofolate reductase (MTHFR) NM_005957 1p36 7
Betaine-homocysteine methyltransferase (BHMT) NM_001713 5q13 4
Cystathionine-β-synthase (CBS) NM_000071 21q22 6
Peroxisome proliferator activated receptor, α (PPARA) NM_005036 22q12 9
Retinoic acid signaling GO:0048384 Retinoic acid receptor, α (RARA) NM_000964 17q21 4
Retinoic acid receptor, β (RARB) NM_016152 3p24 29
Retinoic acid receptor, γ (RARG) NM_000966 12q13 6
Chr, chromosome; SNP, single nucleotide polymorphism.
a
Indicates adjacent genes which were defined by a single genomic region and tagging SNPs. Thus the number of SNPs indicated refers to the total
number of SNPs assayed in the region containing both genes.
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Table 2
Demographic and Clinical Data
Variable HPS (n = 59) No HPS (n = 126) P value
Age (y), mean ± SD 53 ± 9 53 ± 10 .71
Female, n (%) 28 (48) 46 (37) .23
Race/ethnicity, n (%)
 Non-Hispanic white 53 (90) 101 (80) .02
 Hispanic white 2 (3) 16 (13)
 Non-Hispanic black 1 (2) 8 (6)
 Other 3 (5) 1 (1)
Etiology of liver disease, n(%)
Alcohol 23 (39) 54 (43) .62
 Hepatitis C infection 26 (44) 55 (44) .96
 Nonalcoholic steatohepatitis 8 (14) 16 (13) .87
 Cryptogenic cirrhosis 7 (12) 9 (7) .29
 Autoimmune hepatitis 2 (3) 8 (6) .72
 Primary scelrosing cholangitis 2 (3) 8 (6) .51
 Hepatitis B infection 0 (0) 9 (7) .06
 Primary biliary cirrhosis 2 (3) 4 (3) 1
Smoking, n (%) 28 (48) 81 (64) .03
MELD score, mean ± SD 14 ± 4 13 ±5 .7
Intrapulmonary shunt, n (%) 59 (100) 56 (44) <.0001
Arterial blood gas
pH, mean ± SD 7.44 ± 0.03 7.43 ± 0.04 .05
 pCO2 (mm Hg), mean ± SD 34 ± 4 35 ± 5 .32
 pO2 (mm Hg), mean ± SD 75 ± 13 90 ± 15 <.0001
 Alveolar-arterial O2 gradient, mm Hg, median (IQR) 25 (19–35) 10 (4–16) .0001
HPS, hepatopulmonary syndrome; MELD, Model for End-Stage Liver Disease; DLCOcorr, diffusing capacity of the lung for carbon monoxide
corrected for hemoglobin (% predicted).
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